Spruce Biosciences, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026 with the Securities and Exchange Commission on November 9, 2026, disclosing a going concern doubt and a range of material operational risks.

Key Highlights

  • Going concern: The company disclosed that "substantial doubt exists as to our ability to continue as a going concern" due to insufficient working capital to fund planned operations for the next twelve months.
  • Shares outstanding: As of November 5, 2026, the registrant had 2,874,013 shares of common stock, $0.0001 par value per share, outstanding.
  • Lead product candidate: The company is developing tralesinidase alfa enzyme replacement therapy ("TA-ERT"), targeting MPS IIIB, with plans to seek FDA accelerated approval.
  • Program separation: The company disclosed plans to separate its CRHX-101 (formerly known as SPR202) program into a separate entity called Adrenyx, with a planned distribution of Adrenyx shares to stockholders, though completion on the anticipated timeline is not guaranteed.
  • Secured debt risk: The company acknowledged indebtedness to Avenue, secured by substantially all assets including intellectual property, with a disclosed risk of foreclosure upon default.
  • No product revenue: According to the filing, the company currently has no marketing and sales organization and has yet to commercialize a product.

Spruce Biosciences Discloses Going Concern Doubt and Financing Needs in September 2026 Quarterly Filing

Spruce Biosciences, Inc. (NASDAQ:SPRB), a Delaware-incorporated biopharmaceutical company headquartered in South San Francisco, California, filed its Form 10-Q for the quarterly period ended September 30, 2026. The filing prominently flags that the company "does not currently have sufficient working capital to fund our planned operations for the next twelve months," with the registrant stating that "substantial doubt exists as to our ability to continue as a going concern."

The company's primary clinical focus is TA-ERT, its tralesinidase alfa enzyme replacement therapy candidate for MPS IIIB. According to the filing, the company intends to seek FDA approval through the accelerated approval pathway. The registrant cautioned that if accelerated approval is not obtained, additional nonclinical studies or clinical trials beyond the currently contemplated confirmatory Phase 3 trial may be required, increasing expense and delaying potential marketing approval. The filing also noted that the company "will need substantial additional financing" and that failure to obtain it may force a delay, reduction, or elimination of product development programs or commercialization efforts.

The filing additionally disclosed that the CRHX-101 program, formerly known as SPR202, is being separated into a new entity called Adrenyx, with a planned distribution of Adrenyx shares to existing stockholders. The company cautioned that this separation "may not be completed on the anticipated timeline or at all" and "could disrupt our business and divert management attention." Outstanding indebtedness to Avenue, secured by substantially all company assets including intellectual property, was identified as a further risk factor, with potential foreclosure cited as a consequence of default.

What Was Disclosed

Spruce Biosciences filed its Q3 2026 Form 10-Q reporting going concern doubt, insufficient working capital, continued clinical development of TA-ERT for MPS IIIB, a planned spinout of its CRHX-101 program into Adrenyx, and secured debt obligations to Avenue.